Used in the development of targeted protein degradation therapies, particularly in PROTAC (Proteolysis Targeting Chimeras) design. The molecule links a thalidomide derivative, which binds to the E3 ubiquitin ligase cereblon, to a functional amine group via a PEG2 spacer. This allows conjugation to target-binding ligands, enabling selective tagging of disease-related proteins for ubiquitination and subsequent proteasomal degradation. The hydrophilic PEG2 linker improves solubility and pharmacokinetic properties, while the terminal amine facilitates coupling to carboxyl or other activated groups in synthetic routes. Commonly applied in oncology and immunomodulatory drug research.